Loss of function germline mutations in RAD51D in women with ovarian carcinoma

• Published in: Gynecologic oncology Vol. 127; no. 3; pp. 552 - 555
• Main Authors: Wickramanyake, Anneka, Bernier, Greta, Pennil, Christopher, Casadei, Silvia, Agnew, Kathy J, Stray, Sunday M, Mandell, Jessica, Garcia, Rochelle L, Walsh, Tom, King, Mary-Claire, Swisher, Elizabeth M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2012
• Subjects: Adult; Aged; Breast cancer; Breast Neoplasms - genetics; DNA-Binding Proteins - genetics; Female; Germ-Line Mutation; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; Obstetrics and Gynecology; Ovarian cancer; Ovarian Neoplasms - genetics; RAD51D; RAD51D; Breast cancer; Ovarian cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2012.09.009

Abstract Objective RAD51D , a gene in the Fanconi Anemia–BRCA homologous recombination pathway, has recently been shown to harbor germline mutations responsible for ovarian carcinoma in multiply affected families. We aimed to extend these results to ovarian carcinoma in the general population. Methods We sequenced RAD51D in germline DNA from 360 individuals with primary ovarian, peritoneal or fallopian tube carcinoma who were not selected for age of cancer onset or family history. We also sequenced RAD51D in 459 probands from 226 high risk breast cancer families who were wild type for 21 breast and ovarian cancer genes. Results Of 360 cases, three (0.8%) carried loss-of-function mutations in RAD51D . All three subjects had ovarian carcinoma; one was also diagnosed with a synchronous endometrial carcinoma. Only one of the three subjects had a family history of breast or ovarian cancer. Combined with previous data for this series, 23.9% of women with unselected ovarian, fallopian tube, or peritoneal carcinoma carried a germline loss-of-function mutation in any of 13 tumor suppressor genes. Among the 449 women and 10 men with familial breast cancer, none carried a loss of function mutation in RAD51D. Conclusions These data support the previous observation that loss-of-function mutations in RAD51D predispose to ovarian carcinoma but not to breast carcinoma. We conclude that inherited ovarian cancer is highly heterogeneous genetically, and that approximately one in four ovarian carcinoma patients carry a germline mutation in a known tumor suppressor gene that confers high risk.